The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
As our understanding of the mechanisms of cancer treatment has increased, a growing
number of studies demonstrate pathways through which DNA damage repair (DDR) affects …
number of studies demonstrate pathways through which DNA damage repair (DDR) affects …
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
X Peng, W Pan, F Jiang, W Chen, Z Qi, W Peng… - Pharmacological …, 2022 - Elsevier
Poly ADP-ribose polymerase (PARP) plays a critical role in many cellular processes such as
DNA damage repair, gene transcription and cell apoptosis. Therefore, targeting PARP …
DNA damage repair, gene transcription and cell apoptosis. Therefore, targeting PARP …
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
F **ao, ZB Wang, L Qiao, X Zhang, NYY Wu… - Journal of Translational …, 2024 - Springer
The advent of polyadenosine diphosphate ribose polymerase inhibitors (PARPi) has
brought about significant changes in the field of ovarian cancer treatment. However, in 2022 …
brought about significant changes in the field of ovarian cancer treatment. However, in 2022 …
Advances in PARP inhibitors for prostate cancer
S Tisseverasinghe, B Bahoric, M Anidjar, S Probst… - Cancers, 2023 - mdpi.com
Simple Summary Recent practice-changing trials have highlighted the importance of
polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in metastatic castrate …
polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in metastatic castrate …
Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of …
YN Kim, JG Joung, E Park, JW Kim… - … Journal of Cancer, 2023 - Wiley Online Library
Choosing an optimal concomitant drug for combination with poly‐ADP ribose polymerase
(PARP) inhibitor based on patient‐specific biomarker status may help increase to improve …
(PARP) inhibitor based on patient‐specific biomarker status may help increase to improve …
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian …
Ł Biegała, A Gajek, I Szymczak-Pajor, A Marczak… - Scientific Reports, 2023 - nature.com
Olaparib is a PARP inhibitor (PARPi) approved for targeted treatment of ovarian cancer
(OC). However, its efficacy is impeded by the inevitable occurrence of resistance. Here, we …
(OC). However, its efficacy is impeded by the inevitable occurrence of resistance. Here, we …
The current status of DNA-repair-directed precision oncology strategies in epithelial ovarian cancers
H Tang, S Kulkarni, C Peters, J Eddison… - International Journal of …, 2023 - mdpi.com
Survival outcomes for patients with advanced ovarian cancer remain poor despite advances
in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a …
in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a …
SMAD4 limits PARP1 dependent DNA repair to render pancreatic Cancer cells sensitive to Radiotherapy
Y Wang, T Yu, Z Zhao, X Li, Y Song, Y He, Y Zhou… - Cell Death & …, 2024 - nature.com
Dysregulation of SMAD4 (ie somatic mutation) is strongly associated with poor pancreatic
ductal adenocarcinoma (PDAC) prognosis, yet the molecular mechanisms remain …
ductal adenocarcinoma (PDAC) prognosis, yet the molecular mechanisms remain …
Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics
TJ Carneiro, ALMB Carvalho, M Vojtek, IF Carmo… - Cancer Cell …, 2023 - Springer
This work compared the metabolic profile of a parental MDA-MB-231 cisplatin-sensitive
triple negative breast cancer (TNBC) cell line with that of a derived cisplatin-resistant line, to …
triple negative breast cancer (TNBC) cell line with that of a derived cisplatin-resistant line, to …
Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor …
J Zhou, T Du, X Wang, H Yao, J Deng, Y Li… - Journal of Medicinal …, 2023 - ACS Publications
PARP-1/2 inhibitors have become an important therapeutic strategy for the treatment of HR-
deficient tumors. However, discovery of new inhibitors with an improved and distinct …
deficient tumors. However, discovery of new inhibitors with an improved and distinct …